NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,https://clinicaltrials.gov/study/NCT01950182,SYSUCC-002,COMPLETED,The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine Therapy.,NO,Breast Cancer,DRUG: Endocrine therapy combined with trastuzumab|DRUG: Chemotherapy combined with trastuzumab,"progression-free survival (PFS), The interim analysis and the final analysis are expected ot occur 18 and 36 months after the end of recruitment., 36 months",,,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,392,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SYSUCC-002,2013-09-16,2020-05-31,2020-05-31,2013-09-25,,2020-07-15,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China",
